Mattias Carlsten

Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 18

Top Venues

Leukemia

NPJ precision oncology

Clinical & translational immunology

Oncoimmunology

Karolinska Institutet (PHD)

This page only lists publications with an associated author ORCID identifier.

Education History

Karolinska Institutet Jun 01 2006 - Feb 12 2010

Sweden

PHD :: Department of Medicine Huddinge

Karolinska Institutet Aug 15 2000 - Jan 12 2007

Sweden

PHD

Publications

Laura Sanz-Ortega, Agneta Andersson, Mattias Carlsten
Harnessing upregulated E-selectin while enhancing SDF-1α sensing redirects infused NK cells to the AML-perturbed bone marrow. Leukemia (2024)
Laura Sanz-Ortega, Agneta Andersson, Mattias Carlsten
Harnessing upregulated E-selectin while enhancing SDF-1α sensing redirects infused NK cells to the AML-perturbed bone marrow. Leukemia (2024)
Laura Sanz-Ortega, Agneta Andersson, Mattias Carlsten
Harnessing upregulated E-selectin while enhancing SDF-1α sensing redirects infused NK cells to the AML-perturbed bone marrow. Leukemia 38 (3) (2024)
Laura Sanz-Ortega, Caroline Leijonhufvud, Lisanne Schoutens, Mélanie Lambert, Emily Levy, Agneta Andersson, Björn E Wahlin, Mattias Carlsten
Redirecting NK cells to the lymph nodes to augment their lymphoma-targeting capacity. NPJ precision oncology 8 (1) (2024)
Laura Sanz-Ortega, Caroline Leijonhufvud, Lisanne Schoutens, Mélanie Lambert, Emily Levy, Agneta Andersson, Björn E Wahlin, Mattias Carlsten
Redirecting NK cells to the lymph nodes to augment their lymphoma-targeting capacity. NPJ precision oncology 8 (1) (2024)
Laura Sanz-Ortega, Agneta Andersson, Mattias Carlsten
Harnessing upregulated E-selectin while enhancing SDF-1α sensing redirects infused NK cells to the AML-perturbed bone marrow. Leukemia 38 (3) (2024)
Laura Sanz-Ortega, Agneta Andersson, Mattias Carlsten
Harnessing upregulated E-selectin while enhancing SDF-1α sensing redirects infused NK cells to the AML-perturbed bone marrow. Leukemia 38 (3) (2024)
Laura Sanz-Ortega, Agneta Andersson, Mattias Carlsten
Harnessing upregulated E-selectin while enhancing SDF-1α sensing redirects infused NK cells to the AML-perturbed bone marrow. Leukemia 38 (3) (2024)
Laura Sanz-Ortega, Agneta Andersson, Mattias Carlsten
Harnessing upregulated E-selectin while enhancing SDF-1α sensing redirects infused NK cells to the AML-perturbed bone marrow. Leukemia 38 (3) (2024)
Laura Sanz-Ortega, Caroline Leijonhufvud, Lisanne Schoutens, Mélanie Lambert, Emily Levy, Agneta Andersson, Björn E Wahlin, Mattias Carlsten
Redirecting NK cells to the lymph nodes to augment their lymphoma-targeting capacity. NPJ precision oncology 8 (1) (2024)
Laura Sanz-Ortega, Agneta Andersson, Mattias Carlsten
Harnessing upregulated E-selectin while enhancing SDF-1α sensing redirects infused NK cells to the AML-perturbed bone marrow. Leukemia 38 (3) (2024)
Filip Segerberg, Mélanie Lambert, Laura Sanz-Ortega, Agneta Andersson, Richard W Childs, Mattias Carlsten
Improved Leukemia Clearance After Adoptive Transfer of NK Cells Expressing the Bone Marrow Homing Receptor CXCR4 R334X . HemaSphere 7 (11) (2023)
Mattias Carlsten, Yenan T Bryceson
Rough operators: sphingomyelinase inhibitors spike NK cells to kill cancer. Signal transduction and targeted therapy 8 (1) (2023)
Anna Palau, Filip Segerberg, Michael Lidschreiber, Katja Lidschreiber, Aonghus J Naughton, Maria Needhamsen, Lisa Anna Jung, Maja Jagodic, Patrick Cramer, Sören Lehmann, Mattias Carlsten, Andreas Lennartsson
Perturbed epigenetic transcriptional regulation in AML with IDH mutations causes increased susceptibility to NK cells. Leukemia (2023)
John Daly, Subhashis Sarkar, Alessandro Natoni, Jessica C Stark, Nicholas M Riley, Carolyn R Bertozzi, Mattias Carlsten, Michael E O'Dwyer
Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell-mediated tumor responses. Blood advances 6 (11) (2022)
Caroline Leijonhufvud, Robert Reger, Filip Segerberg, Jakob Theorell, Heinrich Schlums, Yenan T Bryceson, Richard W Childs, Mattias Carlsten
LIR-1 educates expanded human NK cells and defines a unique antitumor NK cell subset with potent antibody-dependent cellular cytotoxicity. Clinical & translational immunology 10 (10) (2021)
Mattias Carlsten, Ali Namazi, Robert Reger, Emily Levy, Maria Berg, Cynthia St Hilaire, Richard W Childs
Bortezomib sensitizes multiple myeloma to NK cells via ER-stress-induced suppression of HLA-E and upregulation of DR5. Oncoimmunology 8 (2) (2018)
Hannes Hagström, Anna Andreasson, Axel C Carlsson, Mats Jerkeman, Mattias Carlsten
Body composition measurements and risk of hematological malignancies: A population-based cohort study during 20 years of follow-up. PloS one 13 (8) (2018)

Mattias Carlsten.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Mattias Carlsten